Seratrodast

Seratrodast (AA 2414), an orally active antiasthmatic agent, is a thromboxane A2 receptor (TP) antagonist and ferroptosis inhibitor. Seratrodast reduces lipid ROS production, modulates the systemic xc-/GSH/GPX4 axis, and inhibits JNK phosphorylation and p53 expression. Seratrodast exhibits anti-asthmatic and anti-epileptic activity[1][2][3].

Product Specifications

CAS Number

[112665-43-7]

Product Name Alternative

AA 2414

UNSPSC

12352005

Hazard Statement

H361

Target

Ferroptosis; JNK; MDM-2/p53; Prostaglandin Receptor; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/seratrodast.html

Purity

99.59

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C1=O)=C(C(C(C)=C1C)=O)C(C2=CC=CC=C2)CCCCCC(O)=O

Molecular Formula

C22H26O4

Molecular Weight

354.44

Precautions

H361

References & Citations

[1]Ashida, Y., et al., A novel anti-asthmatic quinone derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins, 1989. 38 (1) : p. 91-112.|[2]Walsh, et al. Killian, AA-2414, an antioxidant and thromboxane receptor blocker, completely inhibits peroxide-induced vasoconstriction in the human placenta. J Pharmacol Exp Ther, 1999. 290 (1) : p. 220-6.|[3]Hao Y, et al. Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation. Brain Res. 2022 Nov 15;1795:148073.